clinical trial · NCT06270030
Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia
PresbyopiaLNZ101 (Aceclidine /Brimonidine) ophthalmic solutionLNZ100 (Aceclidine) ophthalmic solutionPlacebo (Vehicle) ophthalmic solution
brief summary
Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects with Presbyopia
started
Mar 4, 2024
primary completion
Apr 10, 2024
completion
Apr 10, 2024
last updated
Apr 23, 2024
detailed description
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects with Presbyopia
official title
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects With Presbyopia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol